![All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1613cdc1-b321-464f-b17b-ec4249d7b88e/gr1_lrg.jpg)
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer
![A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d0668b16-6f13-4a1b-99c6-7416a2f7b1b3/ctm2346-fig-0002-m.jpg)
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
![Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML](https://www.mdpi.com/biomolecules/biomolecules-10-01387/article_deploy/html/images/biomolecules-10-01387-g001.png)
Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
OAB-001 Potentiating T cell activity against multiple myeloma through SUMOylation inhibition Li Du1, Dennis Awuah1, Wei Liu2, En
OAB-001 Potentiating T cell activity against multiple myeloma through SUMOylation inhibition Li Du1, Dennis Awuah1, Wei Liu2, En
![Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020) Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)](https://jnccn.org/view/journals/jnccn/18/12.5/full-jnccn20-5043f1.jpg)
Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)
![Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients](https://www.frontiersin.org/files/Articles/575168/fonc-10-575168-HTML/image_m/fonc-10-575168-g001.jpg)
Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
![PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma](https://i1.rgstatic.net/publication/326430488_Serum_free_light_chain_levels_and_renal_function_at_diagnosis_in_patients_with_multiple_myeloma/links/5b4d59a7a6fdcc8dae2468c2/largepreview.png)
PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
![US20170137528A1 - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents US20170137528A1 - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents](https://patentimages.storage.googleapis.com/57/01/9c/e44c8fb83ae3ed/US20170137528A1-20170518-D00007.png)
US20170137528A1 - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents
![Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-98803-1/MediaObjects/41598_2021_98803_Fig1_HTML.png)
Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports
![Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data - Clinical Lymphoma, Myeloma and Leukemia Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data - Clinical Lymphoma, Myeloma and Leukemia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/537b0efd-b55e-413f-bb35-9d1e7f18bd3c/gr1_lrg.jpg)